October 27, 2026
Burning Rock Presents STELLA Clinical Validation at ESMO 2026, Exploring an Adjunctive Approach to Differentiating Benign and Malignant Breast Lesions

MADRID, Spain, October 27, 2026 — Burning Rock Biotech Limited (“Burning Rock”) and its clinical collaborators from Jiangsu Province Hospital and the Affiliated Hospital of Qingdao University presented clinical validation results (Poster 2458P) at the European Society for Medical Oncology (ESMO) Congress 2026, exploring STELLA’s potential to support the differentiation of benign and malignant breast lesions as an adjunct to breast imaging.


Accurate differentiation of benign and malignant breast lesions is essential for personalized clinical management. To evaluate the role of liquid biopsy in this setting, Burning Rock and its clinical collaborators conducted the prospective PERCEIVE-BREAST study. The study used Burning Rock’s SPIRAL platform to detect methylation signals and applied STELLA, a tumor-agnostic, DNA methylation-based algorithm, to quantify circulating tumor DNA (ctDNA) levels and evaluate its clinical performance in supporting the differential diagnosis of breast lesions.


Blood samples were prospectively collected before any anti-tumor therapy. The analysis included 516 patients: 395 with invasive breast cancer, 15 with in situ carcinoma, and 106 with benign breast lesions. The study evaluated overall sensitivity and specificity, with further analyses by clinical stage, molecular subtype, and imaging classification.


STELLA achieved 65.9% overall sensitivity and 97.2% specificity. Sensitivity increased with disease stage, reaching 32.7%, 77.4%, 85.3%, and 100.0% in stages I, II, III, and IV, respectively. STELLA also detected 5 of 15 in situ carcinomas, corresponding to a sensitivity of 33.3%. Across molecular subtypes, sensitivity was highest in HR+/HER2+ disease at 89.9%, followed by HR−/HER2− at 81.4%, HR−/HER2+ at 79.5%, and HR+/HER2− at 51.6%.


Among patients classified as BI-RADS category 4 on ultrasound, mammography, or MRI, STELLA demonstrated sensitivities of 55.5%, 59.7%, and 63.3%, respectively, with corresponding specificities of 98.3%, 100.0%, and 95.0%.


These findings highlight STELLA’s potential as an adjunctive tool for differentiating benign and malignant breast lesions. Its high specificity may support its use alongside conventional imaging to help identify a subset of BI-RADS category 4 patients with a high probability of malignancy. Given the lower tumor burden in early-stage disease, a negative result alone cannot rule out malignancy; assessment should integrate follow-up imaging and pathological examination. The research team will also incorporate follow-up data to further explore STELLA’s potential prognostic value in patients with breast cancer.

Learn More
January 06, 2026
Burning Rock’s Liquid Biopsy Technology Granted U.S. Patent, Accelerating Global Layout in Precision Diagnosis
Learn More
December 18, 2025
From Accreditation to Excellence: Webinar Highlights on CAP, CLIA, and Quality Systems in Clinical Laboratories
Learn More
September 24, 2025
Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer
Learn More
July 24, 2025
Burning Rock Dx Laboratory Receives Accreditation from College of American Pathologists
Learn More
October 11, 2024
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Learn More
August 21, 2024
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Learn More
August 21, 2024
Burning Rock Announces the Launch of China’s First Prospective Pan-Cancer Multi-omics Early Detection Study
Learn More
October 31, 2023
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics
Learn More
August 09, 2023
Burning Rock announced a China collaboration with AstraZeneca
Learn More
1 2 3 4
Contact Our Experts
We would like to collect certain personal information about you through cookies and similar technologies in order to personalize the site for you, improve the performance of the site, and support our marketing efforts. By clicking “Accept All”, you confirm that we have your consent to collect and process your personal information in accordance with our Privacy Policy, which may include online targeted and social media advertising in some instances. You can by clicking “Reject All”, you can reject all cookies except for Strictly Necessary Cookies."